In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Thomas Lund^*, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold

^*Corresponding author for this work

Department of Clinical Research
KI, OUH, Research unit of Haematology (Odense)
KI, OUH, Research unit of Radiology (Odense)

Rigshospitalet
Stavanger University hospital
Aarhus University Hospital
Aalborg University Hospital
Zealand University Hospital, Roskilde
Norwegian University of Science and Technology
Karolinska Institute
Oslo University Hospital
University of Oslo

Research output: Contribution to journal › Comment/debate › Research › peer-review

6 Downloads (Pure)

1 Ph.D. thesis

1 results

2024
Treatment and Monitoring of the Bone Disease in Multiple Myeloma Patients
Gundesen, M. T., 8. Jul 2024, Syddansk Universitet. Det Sundhedsvidenskabelige Fakultet. 138 p.
Research output: Thesis › Ph.D. thesis

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Related research output

Search results

Treatment and Monitoring of the Bone Disease in Multiple Myeloma Patients